Hydrochloric Acid

Hydrochloric Acid

SCHEMBL373444

CC[C@H](N)C(N)=O.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2715205 1.00
Hydrochloric Acid SCHEMBL373445 1.00
Hydrochloric Acid SCHEMBL27946874 1.00 SLC1A3 (0.41)
Hydrochloric Acid SCHEMBL28240750 0.97
Hydrochloric Acid SCHEMBL28240747 0.97
SCHEMBL427317 0.97
SCHEMBL31470932 0.97
SCHEMBL428684 0.97
SCHEMBL427318 0.97
SCHEMBL28141431 0.97 SLC1A3 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122071422-A Novel crystal form of (S) -2-aminobutanamide hydrochloride and preparation method and application thereof 浙江华海药业股份有限公司 2026-05-22 CN claimed
CN-120025272-A Preparation method of high-purity levetiracetam 河北创健药业有限公司 2025-05-23 CN claimed
CN-119954668-A Preparation method of (S) -2-aminobutanamide hydrochloride 天方药业有限公司 2025-05-09 CN claimed
CN-118324681-A Salicylic acid(s) -alpha-ethyl-2-oxo-1-pyrrolidine acetamide and crystal structure thereof 浙江理工大学 2024-07-12 CN claimed
CN-118255704-A Synthesis method of levetiracetam 浙江江北药业有限公司 2024-06-28 CN claimed
CN-118221541-A Preparation method of (S) - (+) -2-aminobutanamide hydrochloride 浙江华海药业股份有限公司 2024-06-21 CN claimed
CN-115353475-B Preparation method of levetiracetam 浙江京新药业股份有限公司 2024-04-26 CN claimed
CN-116500151-A HPLC analysis method for (S) -2-aminobutanamide hydrochloride related substances 杭州华东医药集团浙江华义制药有限公司 2023-07-28 CN claimed
CN-109553549-B Preparation of (S) -N- (1-amino-1-oxybutan-2-yl) -4-hydroxybutyramide 万特制药(海南)有限公司 2023-05-09 CN claimed
CN-115353475-A Preparation method of levetiracetam 浙江京新药业股份有限公司 2022-11-18 CN claimed
CN-101735101-A Tartrate of photoactive 2-amino amides BEIJING KANGDACHENG MEDICAL TE 2010-06-16 CN claimed
US-7531673-B2 Preparation of amino acid amides DR. REDDY'S LABORATORIES LIMITED (IN) 2009-05-12 US claimed
CN-101130504-A Synthesis, split and racemization of chirality medicament levetiracetam midbody (S)-(+)-2-amido butyramide hydrochlorate ABA CHEMICALS LTD (CN) 2008-02-27 CN claimed
US-7132552-B2 Process for producing levetiracetam TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2006-11-07 US claimed
CN-1802352-A Process for the preparation of levetiracetam TEVA PHARMA (IL) 2006-07-12 CN claimed
EP-1566376-A1 Preparation of amino acid amides Dr. Reddy's Laboratories Limited (IN) 2005-08-24 EP claimed
US-20050182262-A1 Preparation of amino acid amides DR. REDDY'S LABORATORIES, LIMITED (IN) 2005-08-18 US claimed
EP-1517893-A2 PROCESS FOR PRODUCING LEVETIRACETAM Teva Pharmaceutical Industries Limited (IL) 2005-03-30 EP claimed
US-20040259933-A1 Process for producing levetiracetam TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-12-23 US claimed
WO-2004069796-A2 PROCESS FOR PRODUCING LEVETIRACETAM TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-08-19 WO claimed